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Introduction
In patients with pheochromocytomas it is well known that different 
factors can precipitate an acute pheochromocytoma crisis. Our 
patient presented with a vesicular skin rash and respiratory distress 
suggestive of disseminated varicella zoster for which he was treated 
with steroids and acyclovir. Two days later hypertension was noted 
for the first time.
Case description
A 21-year old male patient was referred to our emergency 
department with dyspnoea, sweating, fever, headache, palpitations, 
non-productive coughing and a vesicular skin rash. The rash started 
first and the other symptoms five days later.
The patient was lucid, with a blood pressure of 140/89 mmHg, a 
pulse rate of 122 beats per minute, a temperature of 37.9°C and 
a respiratory rate of 32 per minute. On examination a few small 
cervical lymph nodes were noted. Examination of his cardiovascular 
system revealed a heaving apex but was otherwise not significant. He 
had bilateral crackles without any bronchial breathing. Respiratory 
distress was evident with nasal flaring, the use of accessory 
respiratory muscles and sub-costal recession. The skin rash was 
diffuse and vesicular in nature, involving his whole body.
A blood gas analysis revealed type 1 respiratory failure. Blood urea, 
creatinine, electrolytes, liver enzyme determinations as well as 
a clotting profile were within normal limits. A full blood count and 
blood platelets were within normal limits. The C-reactive protein 
was 61.1 mg/L. Examination of the urine showed mild proteinuria. 
A chest roentgen plate revealed an interstitial infiltrate. Treatment 
with aciclovir 600 mg 8 hourly IVI and prednisone 60 mg daily 
per os was empirically initiated for suspected disseminated varicella 
zoster infection.
Two days after admission to hospital the patient developed 
significant hypertension of 200/140 mmHg. On subsequent days it 
was noted that the hypertension followed a sinus wave pattern. Thus, 
workup for secondary causes of hypertension was commenced. 
Thyroid functions were normal and a Doppler investigation of the 
renal arteries was within normal limits. No mass lesions could be 
demonstrated in the adrenal glands.
Three 24-hour urine samples were collected for measurement of 
metanephrine excretion. The results are shown in Table I.
A MRI scan was performed which confirmed an extra-adrenal mass 
localised in the left para-aortic area measuring 8.5 x 3.6 cm. This 
was in keeping with a possible pheochromocytoma. 
This was followed by an F-18FDG (F-fluorodeoxy-glucose) PET/CT 
scan which was consistent with a pheochromocytoma. An area of 
intense FDG uptake was also noted in the right axillary lymph nodes, 
suspicious of metastatic disease.
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Table I: 24-hour urine metanephrine results
Urine sample: Metadrenaline Metnoradrenaline
1 2946 nmol/24 h 107439 nmol/24 h
2 931 nmol/24 h 28771 nmol/24 h
3 1066 nmol/24 h 22644 nmol/24 h
Figure 1: F-18FDG PET/CT scan indicating a pheochromocytoma (arrow)
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We have reason to believe that the patient’s blood pressure 
was elevated for a significant time prior to presentation as was 
confirmed by left ventricular hypertrophy on electrocardiogram and 
echocardiogram.
We also considered that the hypertensive crisis was precipitated by 
the use of glucocorticosteroids. This is based on a recently published 
article that reprted four cases of pheochromocytoma crisis induced 
by glucocorticosteroids.1
The patient’s blood pressure was well controlled with doxazosin 
controlled release, atenolol, nifedipine controlled release and 
perindopril prior to surgical removal of a left para-aortic extra-
medullary tumour. Surgery and the post-operative period in the 
intensive care unit were uncomplicated.
Histological examination confirmed the presence of paraganglioma, 
with no involvement of the draining blood vessels. The axillary lymph 
node appeared tumour free, with features of sinus histiocytosis.
Discussion
Pheochromocytomas are tumours that synthesise, store and secrete 
catecholamines. They arise from chromaffin cells derived from 
the embryonic neural crest. Most are located in adrenal medulla 
(80–85%), but it may also develop in or around the sympathetic 
ganglia.2 These extra adrenal pheochromocytomas or paragangliomas 
could occur in thoracic, mediastinal and abdominal or pelvic 
locations, but are predominantly found in the organ of Zuckerland 
(75%).3 This organ is located between the aortic bifurcation and the 
inferior mesenteric artery.4 Less than 10% of these tumours are 
malignant.
Pheochromocytomas arise sporadically or in approximately 25% 
of cases as part of a hereditary syndrome.5 Familial syndromes 
associated with pheochromocytomas include multiple endocrine 
neoplasia type II (IIA and IIB), caused by mutations in the RET proto-
oncogen. A second familial syndrome associated is the Von Hipple-
Lindau (VHL) syndrome where the germ-line mutation involves the 
Von Hipple-Lindau tumour suppressor gene. Neurofibromatosis 
type I, with mutation of the NF 1 suppressor gene as well as the 
familial paraganglioma syndromes 1 and 4 (PGL1 and PGL4) are 
also associated with pheochromocytomas.4,6,7 Recently, two novel 
germ-line mutations were identified resulting in these familial 
paraganglioma syndromes. These involve the gene encoding for 
succinate dehydrogenase (SDH).5,7,8 Mutation of the SDH gene 
subunit D (SDHD) is responsible for PGL1, and in subunit B (SDHB) is 
responsible for PGL4.9
The availability of genetic testing has improved the detection 
of susceptible patients for the development of hereditary 
pheochromocytomas, but controversies for screening recommen-
dations exist. Some authors are of the opinion that all patients 
with catecholamine secreting tumours should be offered genetic 
screening for familial disease.8,10 Others feel that is not cost-effective 
to screen all patients, and recommend that screening should only be 
done in pheochromocytoma patients with a positive family history, 
those with multiple or multifocal tumours, or patients under the age 
of 20 years at time of first diagnosis.2, 11
The clinical features are very non-specific which leads to a delay 
of about three years between the onset of the symptoms and the 
diagnosis.12,13 The majority of symptoms of a pheochromocytoma are 
due to the direct action of secreted catecholamines. This results in 
hypertension with the classic triad of episodic headaches, sweating 
and palpitations. Symptoms of anxiety or panic together with 
metabolic effects such as weight loss, hyperglycaemia and rarely, 
lactic acidosis, may also occur.2,12,14
Hypertension is the most common presenting feature.3,12 This is 
usually sustained and resistant to conventional treatment, although it 
could be paroxysmal in nature. Paroxysms may present as a distinct 
crisis in patients with sustained hypertension. These episodes 
may be serious and can potentially be fatal due to cardiovascular 
complications. This is due to the episodic nature of catecholamine 
secretion, which could be precipitated by stimuli such as micturition, 
certain food and drugs (i.e. tricyclic anti-depressants) or exposure 
to radiographic contrast agents. In a recently published article1 four 
cases of pheochromocytoma crisis were reported, which were most 
likely induced by glucocorticosteroids. Of the four cases reported, 
glucocorticosteroid therapy was associated with a fatal outcome in one 
case, a multisystem crisis in another case, and serious hypertensive 
crisis in the other two. Several isolated cases of pheochromocytoma 
crisis after administration of glucocorticosteroids previously reported 
are mentioned,1 but evidence for this is anecdotal.
Pheochromocytomas are confirmed by biochemical evidence of 
excessive catecholamine production. Catecholamines or their 
metabolites can be measured in either plasma or urine. There is 
still no consensus regarding which biochemical investigation is 
preferred in order to establish a diagnosis.6,15 Measurement of 
plasma metanephrins has a high sensitivity (97–99%), and has been 
recommended as the biochemical test of choice.6,15 Another study has 
concluded that measurement of plasma metanephrins lack specificity 
to be used as a screening test.16 It was recommend that this test is 
the test of choice in high-risk patients with a familial syndrome, but 
measurement of 24-hour metanephrins and catecholamines is more 
specific, making it preferable as a screening test.16,17
Once biochemical evidence for a pheochromocytoma has been 
found, radiological evaluation should follow to locate the tumour. 
Computerised tomography (CT) is the modality most often used as it 
has the advantages of moderate cost, with a sensitivity of 93–100% 
for adrenal tumours3,4 and about 90% for extra adrenal tumours.18 Due 
to the risk of precipitating a hypertensive crisis by the administration 
of radiographic contrast media, patients should be protected by both 
α and β adrenergic receptor blockade. Magnetic resonance imaging 
(MRI) has similar diagnostic sensitivity and has the advantage of not 
exposing the patient to radiographic contrast media. MRI is superior 
to CT imaging in the assessment of the relationship between the 
tumour and the surrounding vessels.4,18 Both CT and MRI have poor 
specificity, reportedly as low as 50%.4 I-metaiodobenzylguanidine 
(MIBG) scintigraphy has a higher specificity, ranging from 95–100%, 
but lower sensitivity of 77–90%.4 MIBG scintigraphy is particularly 
useful in localising tumours detected biochemically, as well as 
detecting recurrent or metastatic pheochromocytomas. It is also 
used to confirm functional tumour tissue localised by CT or MRI.3 
Scintigraphy with 111-In-ocreotide provides another method for 
detecting metastasis, but only limited success has been reported in 
the literature.6,18 Position emission tomography (PET) studies using 
F-fluorodopamine, F-fluorodopa or F-fluorodeoxy-glucose (FDG) 
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may also be used.3,18 FDG, the only PET imaging compound mostly 
used 2 is very successful in detecting metastatic disease, but has 
low specificity.3,18 Due to its cost it is not recommended for the initial 
localisation of the tumour.
Once a pheochromocytoma has been diagnosed, surgical resection 
is the definitive treatment. Induction of anaesthesia before surgery 
or manipulation of the tumour may cause massive catecholamine 
release from the tumour, which can result in a hypertensive crisis, 
myocardial infarction, arrhythmia or stroke.2,6 Prior to surgery 
patients should be adequately prepared in order to prevent these life 
threatening catecholamine induced complications. 
This includes adequate alpha-adrenergic blockade19 with phenoxy-
benzamine, a long acting, non-selective, non-competitive α-blocker 
that has been most commonly used.2,4 Other regimens include the 
use of prazosin and doxazocin. Beta-adrenergic blockade is added 
to oppose the reflex tachycardia associated with α-blockade. Beta 
blockade should only be initiated after α-blockade is established. 
This is because it does not prevent and can augment the effects of 
catecholamines at the α-adrenoreceptors, causing a hypertensive 
crisis. Selective β1-receptor blockers such as atenolol or bisoprolol 
are recommended.19 Calcium channel blockers can be used in 
combination with α-blockers for hypertension control. If used alone, 
they do not completely prevent haemodynamic instability.2 Liberal salt 
and fluid intake from two weeks prior to surgery is recommended, 
to decrease the risk of severe orthostatic hypotension.4 The criteria2 
used to assess adequate preoperative preparation include: 1. Blood 
pressure less than 160/90 mmHg for 24h prior to surgery; 2. The 
presence of orthostatic hypotension, with the blood pressure in 
the upright position not below 80/45mmHg; 3. Not more than one 
ventricular extra systole every five minutes; and 4. No ST-segment 
changes or T-wave inversion seen on the ECG for one week.
Surgical removal of the tumour has previously been performed 
through a trans abdominal incision,3 with palpation of the contra 
lateral adrenal gland and the sympathetic chain to identify other 
possible tumours. Laparoscopic removal of intra- or extra-adrenal 
tumours is now the preferred surgical method,2,3 with the advantages 
of less release of catecholamines, more rapid recovery and shorter 
hospital stay.
There is no curative treatment for malignant pheochromocytomas, 
but surgical resection of the tumour is suggested to control symptoms 
and prolong survival.20 Metastatic lesions should be resected if 
possible and I-MIBG can be used as a therapeutic option in cases 
where the tumour shows uptake.3 This yields partial remission in 
about 25% of patients.
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